MedTrace Logo

The Safety and Efficacy of Jobelyn in the Treatment of Breast Cancer Patients

NCT01936064 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2016-11-01

No results posted yet for this study

Summary

To determine the effective functionality/potency of Jobelyn as an immunologic and haematologic booster in Breast cancer patients (start-off), thus improving the outlook and the quality of life of such patients generally

Conditions

  • Haematological Abnormality

Interventions

DIETARY_SUPPLEMENT

Jobelyn + Cyclophosphamide-Epirubicin6

Jobelyn (dietary Supplement) to be used with Cyclophosphamide-Epirubicin6

DRUG

Placebo + Cyclophosphamide - Epirubicin 6

Routine drugs for the treatment of breast cancer to be used with Placebo

Sponsors & Collaborators

  • Lagos State University

    lead OTHER

Principal Investigators

  • Abiodun Popoola, M.D. · Lagos State University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-10-31
Primary Completion
2017-10-31
Completion
2018-01-31

Countries

  • Nigeria

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01936064 on ClinicalTrials.gov